Leukemia News and Features
A short course of cyclophosphamide can not only prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate need for the typical 6-month round of immune suppression medicines.
For pediatric patients with acute lymphoblastic leukemia (ALL), obesity increases risk of persistent disease
Obese pediatric patients with acute lymphoblastic leukemia (ALL) are more likely to have minimal residual disease.
For younger patients with an acute lymphoblastic leukemia (ALL) subtype, modifying treatment based on chemotherapy response can make a vital difference.
Results of a phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy in a heavily pretreated cohort of patients.
Tyrosine kinase inhibitors (TKIs) may be effective for the treatment of acute lymphoblastic leukemia (ALL).
Leukemia Clinical Trials
- Key discovery in understanding successes and failures of immunotherapy
- Added sugars may increase blood pressure more than high salt consumption
- Researchers identify biological indicator of response to new ovarian cancer drug
- Managing obesity should be part of cancer care
- Galeterone active in one form of castration-resistant prostate cancer
- Importance of sequence in administering premeds with paclitaxel
- Tamoxifen found to lower breast cancer rates among high-risk women in trial
- SABCS: Male breast cancer prognosis falls behind that for women
- Pembrolizumab safe, and even effective in some patients, for triple-negative breast cancer
- Capecitabine does not improve survival in elderly patients with early stage breast cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|